Verenium Achieves Financial Milestone in Research Collaboration with Syngenta
News Jan 10, 2008
Verenium Corporation has announced that it has achieved an important technical milestone associated with a research program with Syngenta AG. As a result of this achievement, Verenium will receive a $500,000 payment from Syngenta.
A core component of this research effort utilized Verenium’s DirectEvolution™ technology to engineer the properties of a key enzyme in the biosynthesis of starch.
“This milestone marks an important validation of Verenium’s evolution technologies in the advancement of high-value crop traits” said Carlos A. Riva, President and Chief Executive Officer at Verenium.
“This progress in the biosynthesis of starch brings the enormous potential of biofuels another step closer,” says Ray Riley, head of research and product development in corn and soybeans for Syngenta.
“Traits specifically designed to increase productivity of biofuels linked with Syngenta elite genetics and input traits that protect the crop’s yield potential are intended to bring increased productivity for growers and cost-effective sustainable production for biofuels manufacturers.”
Big Data Study Targets Genomic Dark Matter from Ocean Floor to Gut FloraNews
An international team led by computational biologist Fran Supek at IRB Barcelona develop a machine learning method to predict unknown gene functions of microbes.The system examines and compares ‘big data’ available on the metagenomes of human and environmental microbiomes.READ MORE
Synthetic Material That Detects Enzymatic ActivityNews
Scientists integrate protein and polymer building blocks to create stimulus-responsive systemsREAD MORE
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.